Understanding Adopting Neoadjuvant Therapy Into Ovarian Cancer
Let's dive into the details surrounding Adopting Neoadjuvant Therapy Into Ovarian Cancer. Bradley J. Monk, MD, FACS, FACOG; Matthew Powell, MD; David O'Malley, MD; and Ursula Matulonis, MD, remark on the role of ...
Key Takeaways about Adopting Neoadjuvant Therapy Into Ovarian Cancer
- R. Wendel Naumann, MD, gynecologic oncologist, Levine
- ... James Tate Thigpen, MD; and Michael J. Birrer, MD, PhD, assess the use of
- Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive ...
- Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
- Leslie Randall, MD, FACOG, discusses new data from the ASCO 2020 virtual meeting, looking at
Detailed Analysis of Adopting Neoadjuvant Therapy Into Ovarian Cancer
Oliver Dorigo, MD, PhD; Bradley J. Monk, MD, FACS, FACOG; Kathleen Moore, MD; Leslie M. Randall, MD, MAS; and Thomas ... Prof Sean Kehoe speaks So for us I think it's important because now that there's more
Linda R. Duska, MD, professor of obstetrics and gynecology, University of Virginia, discusses
That wraps up our extensive overview of Adopting Neoadjuvant Therapy Into Ovarian Cancer.
